Selected article for: "economic crisis and health pandemic"
Author: Guo, Yu; Huang, Lisu; Zhang, Guangshun; Yao, Yanfeng; Zhou, He; Shen, Shu; Shen, Bingqing; Li, Bo; Li, Xin; Zhang, Qian; Chen, Mingjie; Chen, Da; Wu, Jia; Fu, Dan; Zeng, Xinxin; Feng, Mingfang; Pi, Chunjiang; Wang, Yuan; Zhou, Xingdong; Lu, Minmin; Li, Yarong; Fang, Yaohui; Lu, Yun-Yueh; Hu, Xue; Wang, Shanshan; Zhang, Wanju; Gao, Ge; Adrian, Francisco; Wang, Qisheng; Yu, Feng; Peng, Yun; Gabibov, Alexander G.; Min, Juan; Wang, Yuhui; Huang, Heyu; Stepanov, Alexey; Zhang, Wei; Cai, Yan; Liu, Junwei; Yuan, Zhiming; Zhang, Chen; Lou, Zhiyong; Deng, Fei; Zhang, Hongkai; Shan, Chao; Schweizer, Liang; Sun, Kun; Rao, Zihe
Title: A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
  • Cord-id: q82vuel4
  • Document date: 2021_5_11
    • ID: q82vuel4
    Snippet: COVID-19 pandemic caused by SARS-CoV-2 constitutes a global public health crisis with enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can provide an important treatment option to fight COVID-19, especially for the most vulnerable populations. In this work, potent antibodies binding to SARS-CoV-2 Spike protein were identified from COVID-19 convalescent patients. Among them, P4A1 interacts directly with and covers majority of the Receptor Binding Motif of the Spike Recepto
    Document: COVID-19 pandemic caused by SARS-CoV-2 constitutes a global public health crisis with enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can provide an important treatment option to fight COVID-19, especially for the most vulnerable populations. In this work, potent antibodies binding to SARS-CoV-2 Spike protein were identified from COVID-19 convalescent patients. Among them, P4A1 interacts directly with and covers majority of the Receptor Binding Motif of the Spike Receptor-Binding Domain, shown by high-resolution complex structure analysis. We further demonstrate the binding and neutralizing activities of P4A1 against wild type and mutant Spike proteins or pseudoviruses. P4A1 was subsequently engineered to reduce the potential risk for Antibody-Dependent Enhancement of infection and to extend its half-life. The engineered antibody exhibits an optimized pharmacokinetic and safety profile, and it results in complete viral clearance in a rhesus monkey model of COVID-19 following a single injection. These data suggest its potential against SARS-CoV-2 related diseases.

    Search related documents:
    Co phrase search for related documents
    • absence presence and live virus: 1, 2
    • absence presence and load determination: 1
    • absence presence and long term protection: 1, 2
    • absence presence and low quality: 1, 2, 3
    • absence presence and luciferase activity: 1, 2, 3, 4, 5
    • absence presence and luciferase assay: 1
    • absence presence and lung lesion: 1, 2, 3
    • absence presence and lung pathological: 1, 2, 3, 4, 5
    • absence presence and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and lung tissue detect: 1
    • absence presence and macaque model: 1, 2
    • absence presence and magnetic bead: 1, 2, 3
    • accession number and live virus: 1
    • accession number and lung tissue: 1
    • accreditation assessment and lung tissue: 1